Gilenya Halts Brain’s Gray Matter Atrophy in RRMS Patients, Study Suggests
News
Treatment with Gilenya (fingolimod) may limit cerebral gray matter atrophy in relapsing-remitting multiple sclerosis (RRMS) patients, researchers at Boston’s Brigham and Women’s Hospital have found. Their report, ... Read more